Literature DB >> 11291063

Murine models for experimental therapy of pediatric solid tumors with poor prognosis.

C Beltinger1, K M Debatin.   

Abstract

Novel therapeutic strategies are required for pediatric solid tumors with poor prognosis such as metastasizing neuroblastoma, rhabdomyosarcoma and Ewing's sarcoma. A prerequisite for the development of such new therapies is the availability of murine models. To be useful for therapeutic studies, these models should not only recapitulate the genetic alterations characteristic of the human disease but should also mimic the metastatic process and the response to current therapy, both of which ultimately determine the fate of children with these tumors. This review scrutinizes the utility of existing murine models of neuroblastoma, rhabdomyosarcoma and Ewing's sarcoma for investigating novel therapies. Much experience has been gained with both syngeneic and xenogeneic transplantable models of these tumors, while transgenic and knockout mice are just beginning to be available for therapeutic investigations. Modeling the genetic aberrations characterizing these tumors may provide faithful models for therapeutic studies in the future. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11291063     DOI: 10.1002/ijc.1210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  A Pilot Study Into the Use of FDG-mNP as an Alternative Approach in Neuroblastoma Cell Hyperthermia.

Authors:  Mahendran Subramanian; Gillian Pearce; Ozge Kozgus Guldu; Volkan Tekin; Arkadiusz Miaskowski; Omer Aras; Perihan Unak
Journal:  IEEE Trans Nanobioscience       Date:  2016-09       Impact factor: 2.935

2.  Animal models of extracranial pediatric solid tumors.

Authors:  Guido Seitz; Sorin Armeanu-Ebinger; Steven Warmann; Jörg Fuchs
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

3.  Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.

Authors:  Rachel A Burga; Eric Yvon; Elizabeth Chorvinsky; Rohan Fernandes; C Russell Y Cruz; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2019-04-22       Impact factor: 12.531

4.  FDG small animal PET permits early detection of malignant cells in a xenograft murine model.

Authors:  Cristina Nanni; Korinne Di Leo; Roberto Tonelli; Cinzia Pettinato; Domenico Rubello; Antonello Spinelli; Silvia Trespidi; Valentina Ambrosini; Paolo Castellucci; Mohsen Farsad; Roberto Franchi; Andrea Pession; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

5.  Generation and characterization of novel local and metastatic human neuroblastoma variants.

Authors:  Ido Nevo; Orit Sagi-Assif; Liat Edry Botzer; Dana Amar; Shelly Maman; Naam Kariv; Leonor E Leider-Trejo; Larissa Savelyeva; Manfred Schwab; Ilana Yron; Isaac P Witz
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

6.  Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.

Authors:  Shanique A Young; Katelyn E McCabe; Alena Bartakova; Joe Delaney; Donald P Pizzo; Robert O Newbury; Judith A Varner; David D Schlaepfer; Dwayne G Stupack
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

7.  Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation.

Authors:  Fraua Christina Ferlemann; Vishal Menon; Alexandra Larisa Condurat; Jochen Rößler; Jan Pruszak
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.